Format

Send to

Choose Destination
Transpl Infect Dis. 2019 Jul 6. doi: 10.1111/tid.13138. [Epub ahead of print]

Indefinite cytomegalovirus prophylaxis with valganciclovir after lung transplantation.

Author information

1
University of Giessen, and Marburg Lung Center (UGMLC), University Hospital Giessen, Justus Liebig University of Giessen, Giessen, Germany.
2
Department of General and Thoracic Surgery, University Hospital Giessen, Justus Liebig University of Giessen, Giessen, Germany.
3
Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany.
4
Institute of Medical Virology, Justus Liebig University of Giessen, Giessen, Germany.

Abstract

Human cytomegalovirus (HCMV) infections and reactivations are common after lung transplantation and are associated with the development of bronchiolitis obliterans syndrome. Against this background, temporary HCMV prophylaxis is an established standard regimen after lung transplantation in most centres. However, the optimal duration of prophylaxis is unclear. We conducted a retrospective two-centre study to determine the efficacy of indefinite lifelong HCMV prophylaxis with oral valganciclovir in a cohort of 133 lung transplant recipients with a mean follow-up time of approximately 5 years. During the follow-up period, HCMV DNA was detected in 22 recipients (16.5%). In one case, HCMV pneumonitis developed after prophylaxis had been terminated. We observed a beneficial safety profile and tolerability in our cohort, as the majority of patients still received valganciclovir after a 1- and 3-year observation period, respectively. Compared to the literature, these data indicate a beneficial effect of extended valganciclovir prophylaxis with an acceptable safety profile. This article is protected by copyright. All rights reserved.

KEYWORDS:

cytomegalovirus; lung transplantation; valganciclovir

PMID:
31278878
DOI:
10.1111/tid.13138

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center